Stock fact sheet · data as of
Ginkgo Bioworks Holdings, Inc. (DNA): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is DNA undervalued?
At 11.76 (close of 16 Oct 2026), DNA has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -4.68, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files DNA under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for DNA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -2.07 | -118% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 5.00 | -57% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Ginkgo Bioworks Holdings, Inc. scores only 2 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.1/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -33.0%, ROE -61.5%, ROA -27.9% - with debt at 0.86 times equity and negative free cash flow.
Ginkgo Bioworks Holdings, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Service 100% (quarter Q4 FY2025).
Institutional ownership scores 7/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 2 / 9 | ROIC | -33.0% |
|---|---|---|---|
| GLS Moat | 2.1 / 10 | ROE | -61.5% |
| Debt / equity | 0.86 | ROA | -27.9% |
| Free-cash-flow yield | -24.0% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 39: Weak
With a Wheel Score of 39 Ginkgo Bioworks Holdings, Inc. sits in the Weak band. The parts - Value 13/25, Health 4/20, Moat 3/15, Premium 5/20, Stability 14/20 - show where: Health (4/20) scores lowest.
Implied volatility is 119% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (5 of 20) because volatility this high usually comes with a reason. The option chain is deep: 55,870 contracts of open interest across all expiries, which means tight fills at most strikes.
Volume runs at 2.3M shares a day on a market cap of $792M, with a beta of 1.79 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 14 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 4 / 20 | Piotroski 2/9 | |
| Moat | 3 / 15 | moat 2.1/10 | |
| Premium | 5 / 20 | implied volatility 119% | |
| Stability | 14 / 20 | 2.3M shares/day, $792M cap, beta 1.79 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026, 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Ginkgo Bioworks Holdings, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SGP SpyGlass Pharma, Inc. Common Stock | 23.69 | 2.90 | -716% | 8No options | $792M |
| GERN Geron Corporation | 1.23 | - | - | 38Weak | $790M |
| ARDX Ardelyx, Inc. | 3.27 | - | - | 45Weak | $814M |
| ALMS Alumis Inc. | 6.31 | 0.8880 | -611% | 37Weak | $817M |
| AVBP ArriVent BioPharma, Inc. | 16.79 | 1.05 | -1504% | 27Weak | $828M |
| CRVS Corvus Pharmaceuticals, Inc. | 9.85 | 0.0213 | -46156% | 34Weak | $829M |
| ODTX Odyssey Therapeutics, Inc. | 17.57 | - | - | 24No options | $844M |
| ABUS Arbutus Biopharma Corp | 4.29 | 6.25 | +31% | 74Good | $850M |
| LXRX Lexicon Pharmaceuticals, Inc. | 1.65 | - | - | 43Weak | $734M |
| CGEM Cullinan Therapeutics, Inc. | 14.00 | 1.44 | -874% | 22Weak | $860M |
| AKTS Aktis Oncology, Inc. | 16.01 | 2.99 | -436% | 28Weak | $860M |
| KURA Kura Oncology, Inc. | 9.70 | 16.14 | +40% | 45Weak | $863M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about DNA
Is DNA undervalued right now?
The GLS models could not value DNA (the company lost money over the last twelve months, EPS -4.68, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 11.76 against.
What is the Wheel Score of DNA and what does it mean?
DNA scores 39 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for DNA?
None of the nine GLS models produced a positive value for DNA (the company lost money over the last twelve months, EPS -4.68, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Ginkgo Bioworks Holdings, Inc. report earnings next?
The next earnings report is due on 5 Nov 2026, 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does DNA have listed options, and how liquid are they?
Yes. The nightly snapshot found 450 listed contracts with 55,870 open interest across all expiries and implied volatility of 119% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.